Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 121

  • Sort by Relevance to quickly find articles that most closely match your query.

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid derived suppressor cells expressing IL-10, PD-L1 and S100A12.

Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, Le Priol J, Lamy T, Houot R, Le Gouill S, Cartron G, Godmer P, Bouabdallah K, Milpied N, Damaj G, Tarte K, Fest T, Roussel M.

Blood. 2016 Jun 23. pii: blood-2015-08-662783. [Epub ahead of print]


Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.

Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Voldoire M, Guillaume T, Peterlin P, Gallas P, Garnier A, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2016 Aug;95(8):1287-93. doi: 10.1007/s00277-016-2705-z. Epub 2016 Jun 14.


Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.

Souchet L, Levy V, Ouzegdouh M, Tamburini J, Delmer A, Dupuis J, Le Gouill S, Pégourié-Bandelier B, Tournilhac O, Boubaya M, Vargaftig J, Choquet S, Leblond V; FILO (French Innovative Leukemia Organization).

Am J Hematol. 2016 Aug;91(8):782-6. doi: 10.1002/ajh.24405. Epub 2016 Jun 3.


Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults.

Le Bourgeois A, Peterlin P, Guillaume T, Delaunay J, Duquesne A, Le Gouill S, Moreau P, Mohty M, Campion L, Chevallier P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1473-9. doi: 10.1016/j.bbmt.2016.04.015. Epub 2016 Apr 24.


Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.

Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, Maillard N, Tabrizi R, Choquet S, Carras S, Ifrah N, Guillerm G, Mohty M, Tilly H, Socie G, Cornillon J, Hermine O, Daguindau É, Bachy E, Girault S, Marchand T, Oberic L, Reman O, Leux C, Le Gouill S.

Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.102. [Epub ahead of print]


Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G.

Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11.


A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H.

Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24.


Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.

Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, Salles GA, Hoang-Xuan K, Choquet S, Marchand T, Laurent C, Pangault C, Lamy T.

Ann Oncol. 2016 Jul;27(7):1349-50. doi: 10.1093/annonc/mdw138. Epub 2016 Mar 21. No abstract available.


Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.

Lamarque M, Bossard C, Contejean A, Brice P, Parrens M, Le Gouill S, Brière J, Bouabdallah R, Canioni D, Tilly H, Bouchindhomme B, Bachy E, Delarue R, Haioun C, Gaulard P.

Haematologica. 2016 Mar;101(3):e103-6. doi: 10.3324/haematol.2015.135400. Epub 2015 Dec 24. No abstract available.


[Cold-induced skin lesions].

Perrin F, Dejoie T, Le Gouill S, Roland V, Agard C, Hamidou M, Néel A.

Rev Med Interne. 2016 Mar;37(3):217-8. doi: 10.1016/j.revmed.2015.06.015. Epub 2015 Sep 16. French. No abstract available.


BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.

Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, Richardson P, Anderson K, Amiot M, Letai A.

Leukemia. 2016 Mar;30(3):761-4. doi: 10.1038/leu.2015.184. Epub 2015 Jul 15. No abstract available.


Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

Cheminant M, Robinson S, Ribrag V, Le Gouill S, Suarez F, Delarue R, Hermine O.

Expert Rev Hematol. 2015 Aug;8(4):493-504. doi: 10.1586/17474086.2015.1047759. Epub 2015 Jun 19. Review.


Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, Pellat-Deceunynck C, Le Gouill S, Amiot M.

Oncotarget. 2015 Apr 20;6(11):8750-9.


Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.

Brissot E, Clavert A, Blin N, Roland V, Guillaume T, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Gaugler B, Moreau P, Mohty M.

Leukemia. 2015 Oct;29(10):2098-100. doi: 10.1038/leu.2015.64. Epub 2015 Mar 9. No abstract available.


Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators.

N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096.


Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubruille V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S.

Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12.


90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.

Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N.

Ann Oncol. 2015 Jan;26(1):193-8. doi: 10.1093/annonc/mdu503. Epub 2014 Oct 30.


Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.

Lestang E, Caristan A, Néel A, Graveleau J, Duhamel E, Masseau A, Connault J, Maisonneuve H, Le Gouill S, Blin N, Touzeau C, Moreau P, Hamidou M.

Leuk Lymphoma. 2015 Jun;56(6):1895-6. doi: 10.3109/10428194.2014.974595. Epub 2015 Jan 21. No abstract available.


Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.

Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, Guillaume T, Vigouroux S, El-Cheikh J, Delaunay J, Le Gouill S, Moreau P, Labopin M, Chevallier P.

Cancer. 2015 Feb 15;121(4):562-9. doi: 10.1002/cncr.29087. Epub 2014 Oct 3. Erratum in: Cancer. 2015 Mar 1;121(5):800.


Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M; ESMO Guidelines Working Group.

Ann Oncol. 2014 Sep;25 Suppl 3:iii83-92. doi: 10.1093/annonc/mdu264. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk